New rabies shot shows promise in preventing deadly infection after bites
NCT ID NCT03961555
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This study tested a new medicine called SYN023 to prevent rabies in people who were bitten or scratched by animals like dogs or bats. About 448 adults with different levels of rabies risk received either SYN023 or the standard rabies immune globulin, along with the rabies vaccine. The goal was to see if SYN023 works as well as the current treatment to stop rabies from developing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
448 people
The number who actually took part.
- Started
-
Sep 2019
- Finished
-
Dec 2021
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria (Low Risk Group): Subjects must meet all of the following criteria at the time of subject ID assignment: 1. History of dog, cat, mongoose, fox, ferret, skunk, bat or raccoon bite to trunk, leg, ankle or foot, or lick or scratch with, or of broken skin or mucous membrane saliva or neural tissue contamination, unprotected physical bat contact, scratch or saliva contamination of the head or neck without broken skin all ≤ 54 hours 2. Has completed the written informed consent process and signed informed consent document 3. Males and females 4. Is age equal or more than 18 years on Study Day 1 5. Agrees to stay in contact with the study site for the duration of the study, provide updated contact information as necessary, and has no current plans to move from the study area for the duration of the study 6. Lives within 2 hour journey by available transportation to study center 7. For female subjects: agrees to avoid pregnancy from Study Day 1 through Study Day 121. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses if menopausal) in sexual relationships with men must use an acceptable method of avoiding pregnancy during this period. Acceptable methods of avoiding pregnancy include a sterile sexual partner, sexual abstinence (not engaging in sexual intercourse), hormonal contraceptives (oral, injection, transdermal patch, or implant), vaginal ring, intrauterine device (IUD), or the combination of a condom or diaphragm with spermicide Inclusion Criteria (Normal Risk Group) Subjects must meet all of the following criteria at the time of subject ID assignment: 1. History of dog, cat, mongoose, fox, ferret, skunk, bat or raccoon bite to any body part, lick or scratch with, or of broken skin, mucous membrane saliva or neural tissue contamination, or unprotected physical bat contact all ≤ 54 hours from post exposure prophylaxis (PEP) 2. Has completed the written informed consent process and signed informed consent document. 3. Males and females 4. Is age equal or more than 18 years on Study Day 1 5. Agrees to stay in contact with the study site for the duration of the study, provide updated contact information as necessary, and has no current plans to move from the study area for the duration of the study 6. Lives within 2 hour journey by available transportation to study center 7. For female subjects: agrees to avoid pregnancy from agrees to avoid pregnancy from Study Day 1 through Study Day 121. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses if menopausal) in sexual relationships with men must use an acceptable method of avoiding pregnancy during this period. Acceptable methods of avoiding pregnancy include a sterile sexual partner, sexual abstinence (not engaging in sexual intercourse), hormonal contraceptives (oral, injection, transdermal patch, or implant), vaginal ring, intrauterine device (IUD), or the combination of a condom or diaphragm with spermicide Exclusion Criteria: Subjects must have had none of the following at the time of subject ID assignment: 1. Clinical evidence of rabies infection 2. Category 3 exposure \> 54 hours before Study Drug receipt 3. History or serological evidence of previous rabies vaccination 4. Previous receipt of equine or human rabies globulin 5. History of hypersensitivity reaction to equine or human immunoglobulin. 6. Received immunoglobulin or blood products within 42 days before Study Day 1 7. Received any investigational drug therapy or investigational vaccine within 60 days before Study Day 1 8. Planned participation in any other investigational study during the study period. 9. Receiving systemic immunosuppressant medication such as systemic corticosteroids but not limited to systemic corticosteroids 10. History or laboratory evidence of any past, present, or possible immunodeficiency state including but not limited to any laboratory indication of HIV infection 11. Previous medical history that may compromise the safety of the subject in the study according to the opinion of the principal investigator 12. History or evidence on physical examination of any systemic disease or any acute or chronic illness that, in the opinion of the investigator, may interfere with the evaluation of the safety or activity of SYN023 13. Pregnancy (results of the urine pregnancy test MUST be known before enrollment)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Rabies are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asian Hospital and Medical Center
Muntinlupa, National Capital Region, 1780, Philippines
-
Baguio General Hospital and Medical Center
Baguio City, Benguet, 2600, Philippines
-
Center of Excellence in Drug Research, Evaluation and Studies, Inc.
Muntinlupa, National Capital Region, 1781, Philippines
-
Clinical Research Solutions PC -Milan
Milan, Tennessee, 38358, United States
-
De La Salle Health Sciences Institute Independent Ethics Committee
Cavite City, Calabarzon, 4114, Philippines
-
Far Eastern University Hospital Nicanor Reyes Medical Foundation
Quezon City, National Capital Region, 1118, Philippines
-
Manila Doctors Hospital Institutional Review Board
Manila, National Capital Region, 1000, Philippines
-
Mary Johnston Hospital
Manila, Philippines
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Research Institute For Tropical Medicine
Muntinlupa, National Capital Region, 1781, Philippines
-
Southern Philippines Medical Center
Davao City, Davao (Region XI), 8000, Philippines
-
University of Florida
Gainesville, Florida, 32610, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
University of Virginia
Charlottesville, Virginia, 22903, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental antibody cocktail offers hope for rabies patients with no other options
- New antibody cocktail aims to stop rabies after multiple dog bites
- New vaccines for yellow fever and rabies enter first human tests
- New rabies vaccine shows promise in large trial
- Could a tiny skin shot replace the big rabies needle?
- New rabies vaccine passes first safety check in small trial